Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the third National Health and Nutrition Examination Survey (NHANES III)

Prostate

Volumn 62, Issue 1, 2005, Pages 27-33

  Rohrmann, Sabine ^a   De Marzo, Angelo M ^b,c   Smit, Ellen ^d   Giovannucci, Edward ^e,f   Platz, Elizabeth A ^a,b,c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

C reactive protein; Lower urinary tract symptoms; NHANES III; Older men

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGED; ATTENUATION; DISEASE ASSOCIATION; HEALTH SURVEY; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; METABOLIC SYNDROME X; NOCTURIA; NUTRITION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL; PUBLIC HEALTH; RACE; REVIEW; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; URINARY HESITANCY; URINARY TRACT INFECTION;

AGED; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; URINATION DISORDERS;

EID: 10144246588     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20110     Document Type: Review

References (20)

1. Di Silverio F, Gentile V, De Matteis A, Mariotti G, Giuseppe V, Antonio Luigi P, Sciarra A. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: A retrospective analysis. Eur Urol 2003;43(2):164-175.
2. Anjum I, Ahmed M, Azzopardi A, Mufti GR. Prostatic infarction/infection in acute urinary retention secondary to benign prostatic hyperplasia. J Urol 1998;160(3 Pt 1):792-793.
3. Nickel JC, Downey J, Young I, Boag S. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int 1999;84(9):976-981.
4. Gerstenbluth RE, Seftel AD, MacLennan GT, Rao RN, Corty EW, Ferguson K, Resnick MI. Distribution of chronic prostatitis in radical prostatectomy specimens with up-regulation of bcl-2 in areas of inflammation. J Urol 2002;167(5):2267-2270.
5. Neubauer K, Saile B, Ramadori G. Liver fibrosis and altered matrix synthesis. Can J Gastroenterol 2001;15(3):187-193.
6. O'Byrne KJ, Dalgleish AG. Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer 2001;85(4): 473-483.
7. Gleason PE, Jones JA, Regan JS, Salvas DB, Eble JN, Lamph WW, Vlahos CJ, Huang WL, Falcone JF, Hirsch KS. Platelet derived growth factor (PDGF), androgens and inflammation: Possible etiologic factors in the development of prostatic hyperplasia. J Urol 1993;149(6):1586-1592.
8. Anim JT, Udo C, John B. Characterisation of inflammatory cells in benign prostatic hyperplasia. Acta Histochem 1998;100(4): 439-449.
9. National Center for Health Statistics. 1994. Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-1994. Series 1: Programs and collection procedures. Vital Health Stat 1(32):1-407.
10. Gunter EW, Lewis BG, Koncikowski SM. Laboratory procedures used for the Third National Health and Nutrition Examination Survey (NHANES III), 1988-1994. Hyattsville, MD: Centers for Disease Control and Prevention; 1996.
11. Shah BV, Barnwell BG, Bieler GS. SUDAAN user's manual: Software for analysis of correlated data. Research Triangle Park, NC: Research Triangle Institute; 1995.
12. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer 2003;3(4):276-285.
13. Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M, Murphy GP. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 1999;41(2):127-133.
14. Siegsmund MJ, Yamazaki H, Pastan I. Interleukin 6 receptor mRNA in prostate carcinomas and benign prostate hyperplasia. J Urol 1994;151(5):1396- 1399.
15. de Ferranti S, Rifai N. C-reactive protein and cardiovascular disease: A review of risk prediction and interventions. Clinica Chimica Acta 2002;317(1-2):1-15.
16. Latif Z, McMillan DC, Wallace AM, Sattar N, Mir K, Jones G, Underwood MA. The relationship of circulating insulin-like growth factor 1, its binding protein-3, prostate-specific antigen and C-reactive protein with disease stage in prostate cancer. BJU Int 2002;89(4):396-399.
17. Hammarsten J, Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001; 39(2):151-158.
18. Joseph MA, Harlow SD, Wei JT, Sarma AV, Dunn RL, Taylor JMG, James SA, Cooney KA, Doerr KM, Montie JE, Schottenfeld D. Risk factors for lower urinary tract symptoms in a population-based sample of African-American Men. Am J Epidemiol 2003;157(10):906-914.
19. Tamakoshi K, Yatsuya H, Kondo T, Hori Y, Ishikawa M, Zhang H, Murata C, Otsuka R, Zhu S, Toyoshima H. The metabolic syndrome is associated with elevated circulating C-reactive protein in healthy reference range, a systemic low-grade inflammatory state. Int J Obes Relat Metab Disord 2003;27(4):443-449.
20. Platz EA, De Marzo AM, Erlinger TP, Rifai N, Visvanathan K, Hoffman SJ, Helzlsouer KJ. No association between pre-diagnostic C-reactive protein concentration and subsequent prostate cancer. Prostate 2004;59(4):393-400.